LQVTDSGLYRCVIYHPP TFA|西域试剂

LQVTDSGLYRCVIYHPP TFA,99.65%

产品编号：Bellancom-P3400A| 分子式：C₉₁H₁₃₈F₃N₂₃O₂₇S| 分子量：2075.27

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-P3400A	￥750.00	杭州北京（现货）
Bellancom-P3400A	￥1800.00	杭州北京（现货）
Bellancom-P3400A	￥3200.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

LQVTDSGLYRCVIYHPP TFA

产品介绍

LQVTDSGLYRCVIYHPP (LP17) TFA 是一种髓系细胞表达的触发受体 1 (TREM-1) 抑制肽。LQVTDSGLYRCVIYHPP TFA 显著减轻缺血诱导的梗死和神经元损伤。LQVTDSGLYRCVIYHPP TFA 可进入大脑，阻断 TREM-1。

生物活性

LQVTDSGLYRCVIYHPP (LP17) TFA is a triggering receptor expressed on myeloid cells (TREM-1) inhibitory peptide. LQVTDSGLYRCVIYHPP TFA substantially alleviates ischemia-induced infarction and neuronal injury. LQVTDSGLYRCVIYHPP TFA can get access into brain and block TREM-1.

体外研究

LQVTDSGLYRCVIYHPP (LP17) (1 or 10 μM; 24 h) substantially decreases mRNA levels of pro-inflammatory cytokines and chemokines after reoxygenation and remarkably attenuates extracellular protein levels of IL-1β and IL-18 in a microglia oxygen-glucose deprivation (OGD) model.
LQVTDSGLYRCVIYHPP (LP17) (10 μM; 24 h) interacts with microglial SYK.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

RT-PCR

Cell Line:	Primary microglia
Concentration:	1 or 10 μM
Incubation Time:	24 h
Result:	Decreased mRNA levels of NLRP3, IL-1β, IL-18, IL-6, CD16, CD32, iNOS, MCP-1, CXCL-1, and CXCL-2 after reoxygenation.

Western Blot Analysis

Cell Line:	Primary microglia
Concentration:	10 μM
Incubation Time:	24 h
Result:	Suppressed ischemia/reperfusion-induced increments in CARD9, p-p65 in CARD9/NF-κB signaling and NLRP3, ASC, cleaved caspase-1, mature IL-1β, and mature IL-18 in NLRP3/caspase-1 signaling in a microglia oxygen-glucose deprivation (OGD) model.

体内研究
(In Vivo)

LQVTDSGLYRCVIYHPP (LP17) (0.5 or 1 mg/kg; intranasal; daily for 3 days) alleviates ischemia-induced infarction and neuronal injury in mice.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Adult male C57BL/6J mice (20-25 g), mice cerebral ischemia/reperfusion (I/R) model induced by middle cerebral artery occlusion (MCAO)
Dosage:	0.5 mg/kg or 1 mg/kg
Administration:	Intranasal administration, once daily for 3 consecutive days after MCAO
Result:	Abolished ischemia-induced TREM-1 elevation at 1 mg/kg. Significantly reduced infarct volume by 27.3%, induced a markedly reduction in TUNEL positive cells and FJC positive neurons at 1 mg/kg. Rescued neurological deficits and cognitive dysfunction of MCAO mice. Inhibited microglial M1 polarization and neutrophil infiltration.

体内研究

LQVTDSGLYRCVIYHPP (LP17) (0.5 or 1 mg/kg; intranasal; daily for 3 days) alleviates ischemia-induced infarction and neuronal injury in mice.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Adult male C57BL/6J mice (20-25 g), mice cerebral ischemia/reperfusion (I/R) model induced by middle cerebral artery occlusion (MCAO)
Dosage:	0.5 mg/kg or 1 mg/kg
Administration:	Intranasal administration, once daily for 3 consecutive days after MCAO
Result:	Abolished ischemia-induced TREM-1 elevation at 1 mg/kg. Significantly reduced infarct volume by 27.3%, induced a markedly reduction in TUNEL positive cells and FJC positive neurons at 1 mg/kg. Rescued neurological deficits and cognitive dysfunction of MCAO mice. Inhibited microglial M1 polarization and neutrophil infiltration.

体内研究

LQVTDSGLYRCVIYHPP (LP17) (0.5 or 1 mg/kg; intranasal; daily for 3 days) alleviates ischemia-induced infarction and neuronal injury in mice.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Adult male C57BL/6J mice (20-25 g), mice cerebral ischemia/reperfusion (I/R) model induced by middle cerebral artery occlusion (MCAO)
Dosage:	0.5 mg/kg or 1 mg/kg
Administration:	Intranasal administration, once daily for 3 consecutive days after MCAO
Result:	Abolished ischemia-induced TREM-1 elevation at 1 mg/kg. Significantly reduced infarct volume by 27.3%, induced a markedly reduction in TUNEL positive cells and FJC positive neurons at 1 mg/kg. Rescued neurological deficits and cognitive dysfunction of MCAO mice. Inhibited microglial M1 polarization and neutrophil infiltration.

性状

Solid

溶解性数据

In Vitro:

DMSO : ≥ 100 mg/mL (48.19 mM)

H₂O : < 0.1 mg/mL (ultrasonic;adjust pH to 3 with HCl) (insoluble)

* "≥" means soluble, but saturation unknown.

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	0.4819 mL	2.4093 mL	4.8187 mL
5 mM	0.0964 mL	0.4819 mL	0.9637 mL
10 mM	0.0482 mL	0.2409 mL	0.4819 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: ≥ 2.5 mg/mL (1.20 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (1.20 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液
2.

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in saline)
Solubility: 2.5 mg/mL (1.20 mM); Suspended solution; Need ultrasonic

此方案可获得 2.5 mg/mL (1.20 mM) 的均匀悬浊液，悬浊液可用于口服和腹腔注射。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
3.

请依序添加每种溶剂： 10% DMSO 90% corn oil
Solubility: ≥ 2.5 mg/mL (1.20 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (1.20 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。